Non-peptidic chymase inhibitors

Bibliography

• CAUGHEY GH: Serine proteases of mast cell and leukocyte granules. J. Respir. Crit. Care Med. (1994) 150:138–142.
   PubMed Web of Science ®Google Scholar
• FUKAMI H, OKUNISHI H, MIYAZAKI M: Chymase: its pathophysiological roles and inhibitors. Curr. Pharm. Des. (1998) 4:439–453.
   PubMed Web of Science ®Google Scholar
• ••Excellent review on pathophysiological rolesof chymase and chymase inhibitors.
   Google Scholar
• IHARA M, URATA H, KINOSHITA A et el.: Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension (1999) 33:1399–1405
   Google Scholar
• TAKAI S, SHIOTA N, JIN D, MIYAZAKI, M: Chymase processes big-endothelin-2 to endothelin-2-(1-31) that induces contractile responses in the isolated monkey trachea. Eur. J. Pharmcol (1998) 358:229–233.
   PubMedGoogle Scholar
• SHIOTA N, JIN D, TAKAI S et al: Chymase is activated in the hamster heart following ventricular fibrosis during the chronic stage of hypertension. FEBS Lett. (1997) 406:301–304.
   PubMedGoogle Scholar
• HE S, GACA MDA, MCEUEN AR, WALLS AF: Inhibition of chymase as mast cell-stabilizing agents: contribution of chymase in the activation of human mast cells. J. Pharmacol Exp. Ther. (1999) 291:517–523.
   PubMedGoogle Scholar
• MIZUTANI H, SCHECHTER N, LAZARUS G et al: Rapid and specific conversion of precursor interleukin 1 beta (IL-1 beta) to an active IL-1 species by human mast cell chymase. J. Exp. Med. (1991) 174:821–825.
   PubMed Web of Science ®Google Scholar
• LONGLEY BJ, TYRREL L, MA et al: Chymase cleavage of stem cell factor yields a bioactive, soluble product. Proc. Natl Acad. Sci. USA (1997) 94:9017–9021.
   PubMed Web of Science ®Google Scholar
• MAO XQ, SHIRAKAWA T, YOSHIKAWA T et al: Association between genetic variants of mast-cell chymase and eczema. Lancet (1996) 348:581–583.
   PubMed Web of Science ®Google Scholar
• TANAKA K, SUGIURA H, UEHARA Met al.: Association between mast cell chymase genotype and atopic eczema: comparison between patients with atopic eczema alone and those with atopic eczema and atopic respiratory disease. Clin. E. Allergy (1999) 29:800–803.
   Google Scholar
• KOFFORD MW, SCHWARTZ LB, SCHECHTER NM et al: Cleavage of Type I procollagen by human mast cell chymase initiates collagen fibril formation and generates a unique carboxyl-terminal propeptide. J. Biol. Chem. (1997) 272:7127–7131.
   PubMed Web of Science ®Google Scholar
• FANG KC, RAYMOND WW, BLOUNT JL et al.: Dog mast cell alpha-chymase activates progelatinase B by cleaving the Phe88-G1n89 and Phe91-G1u92 bonds of the catalytic domain. J. Biol. Chem. (1997) 272:25628–25635.
   PubMed Web of Science ®Google Scholar
• SHIOTA N, FUKAMIZU A, TAKAI S et al.: Activation of angiotensin II-forming chymase in the cardiomyopatic hamster heart. J. Hypertension (1997) 15:431–440.
   PubMed Web of Science ®Google Scholar
• HAMADA H, TERM M, KIMURA H et al.: Increased expression of mast cell chymase in the lungs of patients with congential heart disease associated with early pulmonary vascular disease. Am. J. Respir. Crit. Care. Med (1999) 160:1303–1308.
   PubMedGoogle Scholar
• TAKAI S, YUDA A, JIN D et al.: Inhibitionof chymase reduces vascular proliferation in dog-grafted veins. FEBS Lett. (2000) 467:141–144.
   PubMedGoogle Scholar
• AOYAMAY, UENAKA M, KONOIKE T et al.: Synthesis and structure-activity relationships of a new class of 1-oxacephem-based human chymase inhibitors. Bioorg. Med. Chem. Lett. (2000) 10:2397–2401.
   PubMedGoogle Scholar
• AOYAMAY, UENAKA M, KONOIKE T et al.: 1-Oxacephen-based human chymase inhibitors: discovery of stable inhibitors in human plasma. Bioorg Med. Chem. Lett. (2000) 10:2403–2406.
   PubMedGoogle Scholar
• NAYA N, KAJIWARA Y, UENAKA M et al.: Effect of a chymase inhibitor in a hamster sponge implant model. 74th Annual Meeting of the Japanese Pharmacological Society, Yokohama, Japan, 21–23 March, 2001, Lecture 175.
   Google Scholar
• ••Describes in vivo data for 1-oxacephem-based human chymase inhibitors.
   Google Scholar
• AOYAMAY, UENAKA M, KIT M et al.: Design, synthesis and pharmacological evaluation of 3-benzylazetidine-2-one-based human chymase inhibitors. Bioorg. Med. Chem. In Press.
   Google Scholar
• •Describes chymase inhibitors which possess high activity and sufficient stability in human plasma.
   Google Scholar
• AKAHOSHI F, ASHIMORI A, YOSHIMURA T et al.: Non-peptidic inhibitors of human chymase. Synthesis, structure-activity relationships, and pharmacokinetic profiles of a series of 5-amino-6-oxo-1,6-dihydropyrimidine-containing trifluoromethyl ketones. Bioorg Med. Chem. (2001) 9:301–315.
   Google Scholar
• AKAHOSHI F, ASHIMORI A, SAKASHITA H et al.: Synthesis, structure-activity relationships, and pharmacokinetic profiles of nonpeptidic difluoromethylene ketones as novel inhibitors of human chymase. J. Med. Chem. (2001) 44:1297–1304.
   PubMedGoogle Scholar
• •Describes pharmacokinetic profiles of novel human chymase inhibitors.
   Google Scholar
• AKAHOSHI F, ASHIMORI A, SAKASHITA H et al.: Synthesis, structure-activity relationships, and pharmacokinetic profiles of nonpeptidic a-keto heterocycles as novel inhibitors of human chymase. J. Med. Chem. (2001) 44:1286–1296
   PubMedGoogle Scholar
• •Describes pharmacokinetic profiles of novel human chymase inhibitors.
   Google Scholar
• IMADA T, KOMORITA N, KOBAYASHI F et al.: Therapeutic potential of specific chymase inhibitor in atopic dermatitis. J. Allergy Clin. Immunol. (2000) 105:S267.
   Google Scholar
• ••Describes first in vivo data for non-peptidichuman chymase inhibitors after oral administration.
   Google Scholar
• NIWATA S, FUKAMI H, SUMIDA M et al.: Substituted 3-(phenylsulfony1)-1-phenylimiciazolidine-2,4-dione derivatives as novel nonpeptide inhibitors of human heart chymase. J. Med. Chem. (1997) 40:2156–2163.
   PubMed Web of Science ®Google Scholar
• HAYASHI Y, IIJIMA K, KATADA J et al.:Structure-activity relationship studies of chloromethyl ketone derivatives for selective human chymase inhibitors. Bioorg: Med Chem. Lett. (2000) 10:199–201.
   PubMed Web of Science ®Google Scholar
• GROUTAS WC, SCHECHTER NM, HE S et al.: Human chymase inhibitors based on the 1,2,5-thiadiazolidine-3-one 1,1-dioxide scaffold. Bioorg: Med. Chem. Lett. (1999) 9:2199–2204.
   Google Scholar